Retroperitoneal Inflammation Detected on FDG PET/CT in Patient on Long-Term Immunotherapy. (1st April 2023)

• Record Type: Journal Article
• Authors: Khessib, Tasnim; Franc, Benjamin; Yang, Eric; Moradi, Farshad
• Is Part Of: Clinical nuclear medicine. Volume 48:Number 4(2023)
• Page Start: e165
• Page End: e166
• Publication Date: 2023-04-01
• Subjects: immunotherapy -- retroperitoneal inflammation -- FDG -- PET/CT -- immune-related adverse effects -- pembrolizumab; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000004513
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract: A 68-year-old man with a history of pulmonary adenocarcinoma on maintenance pembrolizumab presented for surveillance imaging. 18 F-FDG PET/CT demonstrated new ill-defined right retroperitoneal and presacral soft tissue stranding with associated FDG uptake suggestive of inflammation. Biopsy results revealed fibroadipose tissue with extensive lymphoplasmacytic inflammation concerning for immunotherapy-related toxicity. The patient was subsequently taken off pembrolizumab, which he had been on for approximately 3 years. Recognition of immunotherapy-related adverse effects and how they can manifest on 18 F-FDG PET/CT is important for prompt cessation of treatment.